Granules India consolidated Q3 FY26 PAT rises to Rs. 150.21 Cr
Granules India has reported total income of Rs. 1,384.29 crore during the period ended December 31, 2025
Granules India has reported total income of Rs. 1,384.29 crore during the period ended December 31, 2025
Company to launch product after the expiry of semaglutide patent in India
Lupin’s double ‘A’ rating in Climate and Water exemplifies its steadfast commitment to sustainability
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics
This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
Under the deal, ViiV Healthcare will issue new shares to Shionogi for $2.125 billion and cancel Pfizer’s holding
EMA recommended 30 veterinary medicines for marketing authorisation in 2025
Subscribe To Our Newsletter & Stay Updated